Technavio, a US-based global technology research and advisory company, announced on Thursday that the global peptide therapeutics market size is expected to increase by USD17.85bn from 2024 to 2028.
The market size is predicted to increase at a CAGR of 10.03% during the forecast period.
Increasing prevalence of infectious diseases is driving market growth, with a trend towards collaborations for R and D, but complexities in manufacturing, storage conditions, distribution policies, and high cost pose a challenge.
The main market players include Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd. and Worg pharma.
Seegene Inc developing fully automated PCR solution
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Kenox Pharmaceuticals partners with Lactiga US
Nona Biosciences signs licensing agreement with University of Alabama at Birmingham
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies